Id-2 protein expression and microvessel density assessment in various types of malignant ovarian tumors

Background. Recent data indicate that inhibitors of DNA binding/inhibitors of differentiation (Id) protein family (Id-1, -2, -3 and -4) proteins may play a significant role in the progression, neoangiogenesis control and metastases formation of various types of malignancies, including ovarian cancer Aims. Our aim was to assess if the expression of Id2 proteins is associated with selected cinical features and microvessel density in women with malignant ovarian tumors. Material and methods. The study group included 56 women operated because of ovarian cancer. The findings were correlated with the tumor type, histological grading and tumor FIGO stage. Tumor Id2 protein expression was assessed by immunohistochemistry and microvessel density was examined as CD-34 expression. Results. The mean age of the patients was 57± 12,8 (SD) years and 37 (66,1%) of women in this group were postmenopausal. Histological examination revealed that there 27 were serous ovarian cancers (n=27), 12 mucinous cancers, 4 endometrioid cancers and 13 other malignant tumors. Expression of Id2 protein estimated semiquantitatively (as 1 to 9 points) was found in 52 cases. Id2 protein was found in both nuclei and cytoplasm of cancer cells, however, some staining was seen in pericytes adjacent to tumor microcapillary lumen. Patients menopausal status had no influence on the intenstity of protein staining. Low FIGO stage (I and II) tumors had medium or high Id2 expression. Microvessel density, but not Id2 expression was significantly correlated with tumor histological type (p=0,008) with the lowest values found in serous tumors and the highest values found in mucinous cancers. A significant correlation between Id2 expression and MVD was found (R=0,38; p=0,003).The median of MVD was almost twice lower in a group of cancers with low when compared to high Id2 protein expression. Conclusions. Our results indicate that Id2 protein with microvessel density assessment may be used as additional prognostic factors in women with various types of malignant ovarian tumors.

[1]  N. Stachowicz,et al.  Ekspresja białek Id1, epidermalnego czynnika wzrostu (EGF) i jego receptora (EGF-R) w nowotworach złośliwych jajnika , 2010 .

[2]  B. Burwinkel,et al.  Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells , 2010, Breast Cancer Research and Treatment.

[3]  Hong Zhu,et al.  Expression and prognostic value of Id protein family in human breast carcinoma. , 2009, Oncology reports.

[4]  S. Kuo,et al.  Triple negative breast carcinoma is a prognostic factor in Taiwanese women , 2009, BMC Cancer.

[5]  L. Gesualdo,et al.  ID2‐VEGF‐related Pathways in the Pathogenesis of Kaposi's Sarcoma: A Link Disrupted by Rapamycin , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  F. Gao,et al.  Molecular regulation of vasculogenic mimicry in human uveal melanoma cells: role of helix–loop–helix Id2 (inhibitor of DNA binding 2) , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[7]  N. Iizuka,et al.  Decreased ID2 Promotes Metastatic Potentials of Hepatocellular Carcinoma by Altering Secretion of Vascular Endothelial Growth Factor , 2008, Clinical Cancer Research.

[8]  A. Iavarone,et al.  ID proteins as targets in cancer and tools in neurobiology. , 2006, Trends in molecular medicine.

[9]  Y. Wong,et al.  Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). , 2005, Carcinogenesis.

[10]  Michelle A. Schmidt,et al.  Negative acting HLH proteins Id1, Id2, Id3, and Id4 are expressed in prostate epithelial cells , 2005, The Prostate.

[11]  G. Landberg,et al.  High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells , 2005, International journal of cancer.

[12]  A. Iavarone,et al.  Id2 Mediates Tumor Initiation, Proliferation, and Angiogenesis in Rb Mutant Mice , 2005, Molecular and Cellular Biology.

[13]  S. Tsao,et al.  Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells , 2004, British Journal of Cancer.

[14]  M. Schindl,et al.  Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S. Rafii,et al.  The Id proteins and angiogenesis , 2001, Oncogene.

[16]  A. Iavarone,et al.  Id proteins at the cross-road of development and cancer , 2001, Oncogene.

[17]  M. Schindl,et al.  Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. , 2001, Cancer research.

[18]  W. Gerald,et al.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts , 1999, Nature.

[19]  F. Sablitzky,et al.  Id helix-loop-helix proteins in cell growth and differentiation. , 1998, Trends in cell biology.

[20]  G. Viale,et al.  Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas , 1996, International journal of cancer.

[21]  A. Iavarone,et al.  Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins , 1996, Molecular and cellular biology.

[22]  A. Iavarone,et al.  The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. , 1994, Genes & development.

[23]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[24]  C. Perrett,et al.  Angiogenesis in epithelial ovarian cancer , 2002 .